Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS-stimulated co-cultures of periodontal ligament and RAW 264.7 cells, and RANKL-mediated osteoclastogenesis and bone resorption in PBMCs

J Cell Mol Med. 2019 Feb;23(2):1152-1163. doi: 10.1111/jcmm.14015. Epub 2018 Dec 1.

Abstract

Inflammatory mediator prostaglandin E2 (PGE2 ) contributes to bone resorption in several inflammatory conditions including periodontitis. The terminal enzyme, microsomal prostaglandin E synthase-1 (mPGES-1) regulating PGE2 synthesis is a promising therapeutic target to reduce inflammatory bone loss. The aim of this study was to investigate effects of mPGES-1 inhibitors, aminothiazoles TH-848 and TH-644, on PGE2 production and osteoclastogenesis in co-cultures of periodontal ligament (PDL) and osteoclast progenitor cells RAW 264.7, stimulated by lipopolysaccharide (LPS), and bone resorption in RANKL-mediated peripheral blood mononuclear cells (PBMCs). PDL and RAW 264.7 cells were cultured separately or co-cultured and treated with LPS alone or in combination with aminothiazoles. Multinucleated cells stained positively for tartrate-resistant acid phosphatase (TRAP) were scored as osteoclast-like cells. Levels of PGE2 , osteoprotegerin (OPG) and interleukin-6, as well as mRNA expression of mPGES-1, OPG and RANKL were analysed in PDL cells. PBMCs were treated with RANKL alone or in combination with aminothiazoles. TRAP-positive multinucleated cells were analysed and bone resorption was measured by the CTX-I assay. Aminothiazoles reduced LPS-stimulated osteoclast-like cell formation both in co-cultures and in RAW 264.7 cells. Additionally, aminothiazoles inhibited PGE2 production in LPS-stimulated cultures, but did not affect LPS-induced mPGES-1, OPG or RANKL mRNA expression in PDL cells. In PBMCs, inhibitors decreased both osteoclast differentiation and bone resorption. In conclusion, aminothiazoles reduced the formation of osteoclast-like cells and decreased the production of PGE2 in co-cultures as well as single-cell cultures. Furthermore, these compounds inhibited RANKL-induced bone resorption and differentiation of PBMCs, suggesting these inhibitors for future treatment of inflammatory bone loss such as periodontitis.

Keywords: RAW 264.7 cells; aminothiazoles; bone resorption; human PBMCs; lipopolysaccharide; microsomal prostaglandin E synthase-1; osteoclastogenesis; osteoclasts; periodontal ligament cells; prostaglandin E2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Resorption / drug therapy*
  • Bone Resorption / metabolism
  • Cell Differentiation / drug effects
  • Cell Line
  • Coculture Techniques / methods
  • Dinoprostone / metabolism*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Interleukin-6 / metabolism
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / metabolism
  • Lipopolysaccharides / pharmacology
  • Mice
  • Osteoblasts / drug effects
  • Osteoblasts / metabolism
  • Osteoclasts / drug effects*
  • Osteoclasts / metabolism
  • Osteogenesis / drug effects*
  • Osteoprotegerin / metabolism
  • Periodontal Ligament / drug effects*
  • Periodontal Ligament / metabolism
  • Prostaglandin-E Synthases / metabolism
  • RANK Ligand / metabolism*
  • RAW 264.7 Cells
  • Tartrate-Resistant Acid Phosphatase / metabolism
  • Thiazoles / pharmacology*

Substances

  • Interleukin-6
  • Lipopolysaccharides
  • Osteoprotegerin
  • RANK Ligand
  • Thiazoles
  • Tnfsf11 protein, mouse
  • Tartrate-Resistant Acid Phosphatase
  • Prostaglandin-E Synthases
  • Dinoprostone